Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study

W Timothy Garvey, Donna H Ryan, Michelle Look, Kishore M Gadde, David B Allison, Craig A Peterson, Michael Schwiers, Wesley W Day, Charles H Bowden, W Timothy Garvey, Donna H Ryan, Michelle Look, Kishore M Gadde, David B Allison, Craig A Peterson, Michael Schwiers, Wesley W Day, Charles H Bowden

Abstract

Background: Obesity is a serious chronic disease. Controlled-release phentermine/topiramate (PHEN/TPM CR), as an adjunct to lifestyle modification, has previously shown significant weight loss compared with placebo in a 56-wk study in overweight and obese subjects with ≥2 weight-related comorbidities.

Objective: This study evaluated the long-term efficacy and safety of PHEN/TPM CR in overweight and obese subjects with cardiometabolic disease.

Design: This was a placebo-controlled, double-blind, 52-wk extension study; volunteers at selected sites continued with original randomly assigned treatment [placebo, 7.5 mg phentermine/46 mg controlled-release topiramate (7.5/46), or 15 mg phentermine/92 mg controlled-release topiramate (15/92)] to complete a total of 108 wk. All subjects participated in a lifestyle-modification program.

Results: Of 866 eligible subjects, 676 (78%) elected to continue in the extension. Overall, 84.0% of subjects completed the study, with similar completion rates between treatment groups. At week 108, PHEN/TPM CR was associated with significant, sustained weight loss (intent-to-treat with last observation carried forward; P < 0.0001 compared with placebo); least-squares mean percentage changes from baseline in body weight were -1.8%, -9.3%, and -10.5% for placebo, 7.5/46, and 15/92, respectively. Significantly more PHEN/TPM CR-treated subjects at each dose achieved ≥5%, ≥10%, ≥15%, and ≥20% weight loss compared with placebo (P < 0.001). PHEN/TPM CR improved cardiovascular and metabolic variables and decreased rates of incident diabetes in comparison with placebo. PHEN/TPM CR was well tolerated over 108 wk, with reduced rates of adverse events occurring between weeks 56 and 108 compared with rates between weeks 0 and 56.

Conclusion: PHEN/TPM CR in conjunction with lifestyle modification may provide a well-tolerated and effective option for the sustained treatment of obesity complicated by cardiometabolic disease. This trial was registered at clinicaltrials.gov as NCT00796367.

Figures

FIGURE 1.
FIGURE 1.
Trial profile. Standardized lifestyle intervention was used across all treatment groups. Of the 27 subjects who discontinued the study drug because of adverse events during the SEQUEL study, the event began during the CONQUER study for 3 subjects (one in each treatment group). For the remaining 24 subjects, the adverse event leading to discontinuation of the study drug began during the SEQUEL study. *One subject in the 7.5/46 group enrolled in the study but discontinued before receiving the study drug. 7.5/46, 7.5 mg phentermine/46 mg controlled-release topiramate; 15/92, 15 mg phentermine/92 mg controlled-release topiramate.
FIGURE 2.
FIGURE 2.
Mean (95% CI) percentage weight loss from baseline to week 108. LS mean change in the overall study completer sample. Standardized lifestyle intervention was used across all treatment groups. P < 0.0001 compared with placebo at all time points assessed. LOCF, last observation carried forward; LS, least-squares; PHEN/TPM CR 7.5/46, 7.5 mg phentermine/46 mg controlled-release topiramate; PHEN/TPM CR 15/92, 15 mg phentermine/92 mg controlled-release topiramate.
FIGURE 3.
FIGURE 3.
Percentages (and 95% CIs) of subjects achieving ≥5%, ≥10%, ≥15%, or ≥20% weight loss from baseline to week 108 (ITT-LOCF). Standardized lifestyle intervention was used across all treatment groups. *P < 0.0001 compared with placebo; †P = 0.0072 compared with placebo. ITT, intent-to-treat; LOCF, last observation carried forward; PHEN/TPM CR 7.5/46, 7.5 mg phentermine/46 mg controlled-release topiramate; PHEN/TPM CR 15/92, 15 mg phentermine/92 mg controlled-release topiramate.
FIGURE 4.
FIGURE 4.
Effects of PHEN/TPM CR on cardiometabolic variables. LS mean changes (95% CI) in (A) blood pressure, (B) antihypertensive medications, (C) lipid variables, (D) lipid-lowering medications, (E) Hb A1c, and (F) antidiabetic medications from baseline (week 0) to week 108 (ITT-LOCF). Changes in Hb A1c represent the T2D subgroup. Changes in concomitant medications represent the safety study. Standardized lifestyle intervention was used across all treatment groups. *Percentage increase minus percentage decrease; P < 0.05 for between-group differences. †P < 0.01 compared with placebo; ‡P < 0.0001 compared with placebo. Hb A1c, glycated hemoglobin; HDL-C, HDL cholesterol; ITT, intent-to-treat; LDL-C, LDL cholesterol; LOCF, last observation carried forward; LS, least-squares; PHEN/TPM CR 7.5/46, 7.5 mg phentermine/46 mg controlled-release topiramate; PHEN/TPM CR 15/92, 15 mg phentermine/92 mg controlled-release topiramate; T2D, type 2 diabetes.
FIGURE 5.
FIGURE 5.
Annualized incidence rate for progression to T2D. Data represent subjects without T2D at baseline. Standardized lifestyle intervention was used across all treatment groups. *P = 0.1514 compared with placebo; †P = 0.0078 compared with placebo. PHEN/TPM CR 7.5/46, 7.5 mg phentermine/46 mg controlled-release topiramate; PHEN/TPM CR 15/92, 15 mg phentermine/92 mg controlled-release topiramate; T2D, type 2 diabetes.

References

    1. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010;303:235–41
    1. Pi-Sunyer X. The medical risks of obesity. Postgrad Med 2009;121:21–33
    1. Delaet D, Schauer D. Obesity in adults. Clin Evid (Online) 2011. Available from: (cited 10 October 2011)
    1. Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006;444:881–7
    1. Flegal KM, Graubard BI, Williamson DF, Gail MH. Cause-specific excess deaths associated with underweight, overweight, and obesity. JAMA 2007;298:2028–37
    1. Klein S, Burke LE, Bray GA, Blair S, Allison DB, Pi-Sunyer X, Hong Y, Eckel RH; American Heart Association Council on Nutrition, Physical Activity, and Metabolism Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 2004;110:2952–67
    1. Logue J, Murray HM, Welsh P, Shepherd J, Packard C, Macfarlane P, Cobbe S, Ford I, Sattar N. Obesity is associated with fatal coronary heart disease independently of traditional risk factors and deprivation. Heart 2011;97:564–8
    1. National Heart, Lung, and Blood Institute, NIH, US Department of Health and Human Services Identification, evaluation, and treatment of overweight and obesity in adults. Washington, DC: National Heart, Lung, and Blood Institute, 2000. (NIH publication no. 00-4048.)
    1. Colquitt JL, Picot J, Loveman E, Clegg AJ. Surgery for obesity. Cochrane Database Syst Rev 2009;CD003641
    1. Hussain SS, Bloom SR. The pharmacological treatment and management of obesity. Postgrad Med 2011;123:34–44
    1. Melnikova I, Wages D. Anti-obesity therapies. Nat Rev Drug Discov 2006;5:369–70
    1. Bray GA, Hollander P, Klein S, Kushner R, Levy B, Fitchet M, Perry BH. A 6-month randomized, placebocontrolled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 2003;11:722–33
    1. Rosenstock J, Hollander P, Gadde KM, Sun X, Strauss R, Leung A. A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients. Diabetes Care 2007;30:1480–6
    1. Tonstad S, Tykarski A, Weissgarten J, Ivleva A, Levy B, Kumar A, Fitchet M. Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension. Am J Cardiol 2005;96:243–51
    1. Toplak H, Hamann A, Moore R, Masson E, Gorska M, Vercruysse F, Sun X, Fitchet M. Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Int J Obes (Lond) 2007;31:138–46
    1. Wilding J, Van Gaal L, Rissanen A, Vercruysse F, Fitchet M. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes Relat Metab Disord 2004;28:1399–410
    1. Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, Day WW. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:1341–52
    1. Brownell K. The LEARN program for weight management. Dallas, TX: The Life Style Company, 2000
    1. American Diabetes Association Standards of medical care in diabetes—2007. Diabetes Care 2007;30(suppl 1):S4–41
    1. American Diabetes Association Standards of medical care in diabetes—2011. Diabetes Care 2011;34(suppl 1):S11–61
    1. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC, Jr; International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640–5
    1. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Jr, et al. ; American Heart Association; National Heart, Lung, and Blood Institute Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735–52
    1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595–607
    1. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120:713–9
    1. Petrilla AA, Benner JS, Battleman DS, Tierce JC, Hazard EH. Evidence-based interventions to improve patient compliance with antihypertensive and lipid-lowering medications. Int J Clin Pract 2005;59:1441–51
    1. Medical Dictionary for Regulatory Activities. Available from: (cited 10 December 2010)
    1. Leitzmann MF, Moore SC, Koster A, Harris TB, Park Y, Hollenbeck A, Schatzkin A. Waist circumference as compared with body-mass index in predicting mortality from specific causes. PLoS ONE 2011;6:e18582.
    1. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403
    1. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The DaQing IGT and Diabetes Study. Diabetes Care 1997;20:537–44
    1. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, et al. Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343–50
    1. Lindström J, Louheranta A, Mannelin M, Rastas M, Salminen V, Eriksson J, Uusitupa M, Tuomilehto J; Finnish Diabetes Prevention Study Group The Finnish Diabetes Prevention Study (DPS): lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 2003;26:3230–6
    1. Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, Hill JO, Brancati FL, Peters A, Wagenknecht L; Look AHEAD Research Group Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care 2011;34:1481–6
    1. Tzotzas T, Evangelou P, Kiortsis DN. Obesity, weight loss and conditional cardiovascular risk factors. Obes Rev 2011;12:e282–9
    1. DeMaria EJ. Bariatric surgery for morbid obesity. N Engl J Med 2007;356:2176–83
    1. International Diabetes Federation Consensus Panel Bariatric surgical and procedural interventions in the treatment of obese patients with type 2 diabetes: a position statement from the International Diabetes Federation Taskforce on Epidemiology and Prevention. Available from: (cited 10 October 2011)

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere